With fine-tuned AI models, OpenAI, Babylon aim to predict clinical trial successes
The company behind ChatGPT and the biotech startup have been working to tailor models specifically to identify the pitfalls that may cause a promising molecule to miss its primary endpoint, through a process called reinforcement fine-tuning.
The company behind ChatGPT and the biotech startup have been working to tailor models specifically to identify the pitfalls that may cause a promising molecule to miss its primary endpoint, through a process called reinforcement fine-tuning.
